Core Viewpoint - The stock of 基石药业-B (02616) has seen a significant increase, rising over 9% in early trading, indicating strong market interest and confidence in the company's long-term value [1] Group 1: Stock Performance - As of the latest update, the stock price reached 5.98 HKD, with a trading volume of approximately 20.69 million HKD [1] - The stock experienced an increase of 8.93% at the time of reporting [1] Group 2: Institutional Investment - Singapore's Government Investment Corporation (GIC) has increased its stake in 基石药业 by acquiring 1.7955 million shares at a price of 5.4692 HKD per share, totaling around 9.82 million HKD [1] - Following this acquisition, GIC's total shareholding rose to approximately 10.5 million shares, representing a 7.11% ownership stake [1] - GIC has steadily increased its holdings from 5.49% on August 18 to 6.00% on October 13, and now to 7.11% within a span of less than three months, reflecting growing confidence in the company's long-term prospects [1] Group 3: Company Management Confidence - The company's CEO, 杨建新, along with other key executives, has also shown confidence by purchasing additional shares of the company since the second half of this year [1]
港股异动 | 基石药业-B(02616)早盘涨超9% GIC继续增持公司股份 持股比例已突破7%